Inactive Instrument

HLS Therapeutics Inc Stock Toronto S.E.

Equities

AM

CA05328X1015

Pharmaceuticals

Sales 2024 * 56.7M 77.49M Sales 2025 * 62.27M 85.1M Capitalization 80.12M 110M
Net income 2024 * -23M -31.43M Net income 2025 * -21M -28.7M EV / Sales 2024 * 1.41 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.29 x
P/E ratio 2024 *
-4.18 x
P/E ratio 2025 *
-5.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.64%
More Fundamentals * Assessed data
Dynamic Chart
National Bank on DRI Healthcare Trust's Xenpozyme Royalty Stream Acquisition MT
HLS Therapeutics Sells Xenpozyme Royalty Interest to DRI Healthcare Trust MT
HLS Therapeutics Brief: Announcing Sale of its XENPOZYME Royalty Interest to DRI Healthcare Trust MT
Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call
HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study MT
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment CI
Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance MT
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023. CI
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million MT
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024 CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023. CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022. CI
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA CI
More news

Latest transcript on HLS Therapeutics Inc

Managers TitleAgeSince
Chief Executive Officer 56 23-04-30
Director of Finance/CFO - 23-06-21
Compliance Officer 43 18-05-06
Members of the board TitleAgeSince
Chairman 46 21-06-17
Director/Board Member 66 19-03-20
Director of Finance/CFO - 23-06-21
More insiders
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
More about the company